Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents

Journal of Medicinal Chemistry

Volumn 52, Issue 10, 2009, Pages 3248-3258

  Qian, Keduo ^a   Yu, Donglei ^a   Chen, Chin Ho ^b   Huang, Li ^b   Morris Natschke, Susan L ^a   Nitz, Theodore J ^c   Salzwedel, Karl ^c   Reddick, Mary ^c   Allaway, Graham P ^c   Lee, Kuo Hsiung ^a  

^a University of North Carolina   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Panacos Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[(N (3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL) 7 AMINOHEPTYL)CARBAMOYL]METHANE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA HYDROXY 30 (2' MORPHOLINOETHOXY)LUP 20 (29) EN 28 OYL [8 AMINOOACTANOYL]AMINOMETHANE; BETULIC ACID; BEVIRIMAT; BUSPIRONE; N [3 BETA HYDROXY 30 (2' MORPHOLINOETHOXY) LUP 20 (29) EN 28 OYL] 8 AMINOOCTANOIC ACID; N [3 BETA HYDROXY 30 (2' MORPHOLINOETHOXY) LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 (4' BROMOPHENETHOXY) LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 (4' CHLOROMOPHENETHOXY) LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 (4' FLUOROPHENETHOXY) LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 (4' METHOXYPHENETHOXY) LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 BUTOXY LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 ETHOXY LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 MORPHOLINO LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 PHENETHOXY LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY 30 PROPOXY LUP 20 (29) EN 28 OYL]LEUCINE; N [3 BETA HYDROXY LUP 20 (29) EN 28 OYL]PIPERIDINEBUTYRIC ACID; N [3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL]PIPERIDINEBUTYRIC ACID; N [3 BETA O (4',4' DIMETHYLGLUTARYL)LUP 20 (29) EN 28 OYL]PIPERIDINEBUTYRIC ACID; N' [3 BETA N (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL]LEUCINE; N' [3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL] 4 PIPERIDINEBUTANOYL]AMINOMETHANE; N' [N (3 BETA HYDROXYLUP 20 (29) EN 28 OYL) 8 AMINOOCTANOYL] 4 AMINO 3 HYDROXY 6 METHYLHEPTANOIC ACID; N' [N (3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL) 4 PIPERIDINEBUTANOYL] 2 AMINOETHYLMORPHOLINE; N' [N (3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL) 4 PIPERIDINEBUTANOYL] 2 AMINOPROPYLMORPHOLINE; N' [N (3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20 (29) EN 28 OYL) 4 PIPERIDINEBUTANOYL]MORPHOLINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER MICROSOME;

ANTI-HIV AGENTS; DRUG DESIGN; DRUG STABILITY; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRITERPENES;

EID: 66249103295     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900136j     Document Type: Article

References (35)

1. UNAIDS. AIDS epidemic update, December 2007.
2. Barbaro, G.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. 2005, 11, 1805-1843.
3. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995, 373, 123-126.
4. Hammer, S. M.; Katzenstein, D. A.; Hughes, M. D.; Gundacker, H.; Schooley, R. T.; Haubrich, R. H.; Henry, W. K.; Lederman, M. M.; Phair, J. P.; Niu, M.; Hirsch, M. S.; Merigan, T. C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 1996, 335, 1081-1090.
5. Gulick, R. M.; Meibohm, A.; Havlir, D.; Eron, J. J.; Mosley, A.; Chodakewitz, J. A.; Isaacs, R.; Gonzalez, C.; McMahon, D.; Richman, D. D.; Robertson, M.; Mellors, J. W. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003, 17, 2345-2349. (Pubitemid 38147020)
6. Chun, T. W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J. A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T. C.; Kuo, Y. H.; Brookmeyer, R.; Zeiger, M. A.; Barditch-Crovo, P.; Siliciano, R. F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (London) 1997, 387, 183-188. (Pubitemid 27209433)
7. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L. M.; Buck, C.; Chaisson, R. E.; Quinn, T. C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D. D.; Richman, D. D.; Siliciano, R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278, 1295-1300. (Pubitemid 27495742)
8. Wong, J. K.; Hezareh, M.; Gunthard, H. F.; Havlir, D. V.; Ignacio, C. C.; Spina, C. A.; Richman, D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278, 1291-1295. (Pubitemid 27495741)
9. Piscitelli, S. C.; Flexner, C.; Minor, J. R.; Polis, M. A.; Masur, H. Drug interactions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 1996, 23, 685-693.
10. Louie, M.; Markowitz, M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res. 2002, 55, 15-25. (Pubitemid 34655639)
11. Boden, D.; Hurley, A.; Zhang, L.; Cao, Y.; Guo, Y.; Jones, E.; Tsay, J.; Ip, J.; Farthing, C.; Limoli, K.; Parkin, N.; Markowitz, M. HIV-1 drug resistance in newly infected individuals. JAMA, J. Am. Med. Assoc. 1999, 282, 1135-1141. (Pubitemid 29441957)
12. Wegner, S. A.; Brodine, S. K.; Mascola, J. R.; Tasker, S. A.; Shaffer, R. A.; Starkey, M. J.; Barile, A.; Martin, G. J.; Aronson, N.; Emmons, W. W.; Stephan, K.; Bloor, S.; Vingerhoets, J.; Hertogs, K.; Larder, B. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000, 14, 1009-1015. (Pubitemid 30336062)
13. Hammer, S. M.; Pedneault, L. Antiretroviral resistance testing comes of age. Antiviral Ther. 2000, 5, 23-26.
14. Fujioka, T.; Kashiwada, Y.; Kilkuskie, R. E.; Cosentino, L. M.; Ballas, L. M.; Jiang, J. B.; Janzen, W. P.; Chen, I. S.; Lee, K. H. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J. Nat. Prod. 1994, 57, 243-247.
15. Kashiwada, Y.; Hashimoto, F.; Cosentino, L. M.; Chen, C. H.; Garrett, P. E.; Lee, K. H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J. Med. Chem. 1996, 39, 1016-1017.
16. Li, F.; Goila-Gaur, R.; Salzwedel, K.; Kilgore, N. R.; Reddick, M.; Matallana, C.; Castillo, A.; Zoumplis, D.; Martin, D. E.; Orenstein, J. M.; Allaway, G. P.; Freed, E. O.; Wild, C. T. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13555-13560.
17. Yu, D.; Wild, C. T.; Martin, D. E.; Morris-Natschke, S. L.; Chen, C. H.; Allaway, G. P.; Lee, K. H. The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. Expert Opin. Invest. Drugs 2005, 14, 681-693.
18. Martin, D. E.; Blum, R.; Wilton, J.; Doto, J.; Galbraith, H.; Burgess, G. L.; Smith, P. C.; Ballow, C. Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob. Agents Chemother. 2007, 51, 3063-3066.
19. Smith, P. F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G. P.; Martin, D. E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother. 2007, 51, 3574-3581.
20. Soler, F.; Poujade, C.; Evers, M.; Carry, J. C.; Henin, Y.; Bousseau, A.; Huet, T.; Pauwels, R.; De Clercq, E.; Mayaux, J. F.; Le Pecq, J. B.; Dereu, N. Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. J. Med. Chem. 1996, 39, 1069-1083.
21. Labrosse, B.; Treboute, C.; Alizon, M. Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J. Virol. 2000, 74, 2142-2150. (Pubitemid 30091467)
22. Sun, I. C.; Chen, C. H.; Kashiwada, Y.; Wu, J. H.; Wang, H. K.; Lee, K. H. Anti-AIDS agents. 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid. J. Med. Chem. 2002, 45, 4271-4275.
23. Qian, K.; Morris-Natschke, S. L.; Lee, K. H. HIV entry inhibitors and their potential in HIV therapy. Med. Res. Rev. 2009, 29, 369-393.
24. Mayaux, J. F.; Bousseau, A.; Pauwels, R.; Huet, T.; Henin, Y.; Dereu, N.; Evers, M.; Soler, F.; Poujade, C.; De Clercq, E.; et al. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3564-3568.
25. Lai, W.; Huang, L.; Ho, P.; Li, Z.; Montefiori, D.; Chen, C. H. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2008, 52, 128-136.
26. Huang, L.; Zhang, L.; Chen, C. H. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. Curr. Pharm. Des. 2003, 9, 1453-1462.
27. Evers, M.; Poujade, C.; Soler, F.; Ribeill, Y.; James, C.; Lelievre, Y.; Gueguen, J. C.; Reisdorf, D.; Morize, I.; Pauwels, R.; De Clercq, E.; Henin, Y.; Bousseau, A.; Mayaux, J. F.; Le Pecq, J. B.; Dereu, N. Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action. J. Med. Chem. 1996, 39, 1056-1068.
28. Huang, L.; Yuan, X.; Aiken, C.; Chen, C. H. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob. Agents Chemother. 2004, 48, 663-665.
29. Wen, Z.; Martin, D. E.; Bullock, P.; Lee, K. H.; Smith, P. C. Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab. Dispos. 2007, 35, 440-448.
30. Huang, L.; Ho, P.; Lee, K. H.; Chen, C. H. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. Bioorg. Med. Chem. 2006, 14, 2279-2289.
31. Sun, I. C.; Wang, H. K.; Kashiwada, Y.; Shen, J. K.; Cosentino, L. M.; Chen, C. H.; Yang, L. M.; Lee, K. H. Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents. J. Med. Chem. 1998, 41, 4648-4657.
32. Leeds, J. P.; Kirst, H. A. A mild single-step reduction of oximes to amines. Synth. Commun. 1988, 18, 777-782.
33. Qian, K.; Nakagawa-Goto, K.; Yu, D.; Morris-Natschke, S. L.; Nitz, T. J.; Kilgore, N.; Allaway, G. P.; Lee, K. H. Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl- betulinic acid derivatives. Bioorg. Med. Chem. Lett. 2007, 17, 6553-6557.
34. Roehm, N. W.; Rodgers, G. H.; Hatfield, S. M.; Glasebrook, A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 1991, 142, 257-265.
35. Yu, D.; Sakurai, Y.; Chen, C. H.; Chang, F. R.; Huang, L.; Kashiwada, Y.; Lee, K. H. Anti-AIDS agents. 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents. J. Med. Chem. 2006, 49, 5462-5469.